• Home
  • About
    • Psychedelic For Healthy People
    • Psilocybin (Magic Mushrooms)
    • Ayahuasca (Chacruna – Kaapi – Yajé)
    • MDMA (MDA – Sassafras)
    • Peyote Mescaline (Huachuma)
    • Kambo – Amazonian Frog
    • 5-MeO-DMT (Toad Medicine)
    • Rapé And Sacred Tobacco
    • Iboga (Ibogaine)
    • LSD (Lysergic Acid Diethylamide)
    • Cannabis (Marijuana)
    • Ketamine
    • Psychedelic Integration
    • Psychedelics Advocates
    • Frequently Asked Questions
    • Mental Health Symptoms
    • Substances Test Kits
    • Manifesto
  • Treatments
    • Latest Psychedelic Research
    • Addiction
    • Alcoholism
    • Anxiety
    • Bipolar Disorder
    • Cancer
    • Cluster Headaches
    • Depression
    • End Of Life
    • OCD
    • Neuropathy
    • Pain
    • Parkinson’s Disease
    • PTSD
    • Smoking
    • Help Treat Mental Illness
  • Microdosing
    • What is Microdosing?
    • Microdosing Magic Mushrooms
    • Microdosing LSD
    • Microdosing MDMA
    • Microdosing Ayahuasca
    • Microdosing Mescaline
    • Microdosing Cannabis
    • Microdosing Ibogaine
  • Resources
    • Past Events
    • ALL Locations
    • DMT Psychoactive Plants
    • Medical Trials And Research
    • Psychedelic Research
    • EntheoPodcasts
    • In The News
    • Books On Psychedelics
    • Related Videos
    • EntheoResources
    • Terence McKenna
    • What Is Psychedelic Art?
    • Useful Links
    • Movies & Documentaries
    • Michael Pollan
Contact
  • Follow
  • Follow
  • Follow
  • Follow
Can a Company Patent the Basic Components of Psychedelic Therapy?

Can a Company Patent the Basic Components of Psychedelic Therapy?

by EmpathiCSubstanceS | Nov 9, 2021 | Cluster Headaches, DMT, LSD, NN-Dimethyltryptamine

Graham Pechenik, a patent and intellectual property (IP) lawyer, recently tweeted about claims he found surprising in a pending application for psychedelic therapy using psilocybin, the hallucinogenic ingredient in magic mushrooms. Claims are the meat and potatoes of...
Can a Company Patent the Basic Components of Psychedelic Therapy?

Is it Possible to Create an Ethical Psychedelics Company?

by EmpathiCSubstanceS | Nov 9, 2021 | Cancer, CBC, Cluster Headaches, Depression, MDMA Sassafras Molly, Neuropathy, NN-Dimethyltryptamine

At a virtual investment conference last week called Psychedelic Capital, the moderator of a session on ethical intellectual property opened the panel by asking, “To patent or not patent? That is the question.” That certainly is the question that’s been hotly debated...
Can a Company Patent the Basic Components of Psychedelic Therapy?

Do Psychedelics Just Provide Comforting Delusions?

by EmpathiCSubstanceS | Nov 8, 2021 | Addiction, Alcoholism, Ayahuasca, Cancer, Cluster Headaches, Depression, Iboga, Kambo, Parkinson's Disease, Psychotropics

And if so, does it matter? In a new book, philosopher Chris Letheby confronts the nature and implications of the mystical experiences people often have while taking psychedelics. There’s an “elephant in the room” of psychedelic science, according to an opinion...
Can a Company Patent the Basic Components of Psychedelic Therapy?

Can LSD Treat Food Allergies?

by EmpathiCSubstanceS | Nov 8, 2021 | Anxiety, Bipolar Disorder, Cannabis Marijuana, Chronic Pain, Depression, Kambo, LSD, NN-Dimethyltryptamine, Pain, San Pedro Mescaline

We Don’t Know, But It’s Already Been Patented. In 2001, alternative medicine proponent and doctor Andrew Weil told a CBS journalist that taking LSD cured his lifelong cat allergy. “I was in a wonderful outdoor setting,” Weil said. “I felt terrific and, in the midst of...
Can a Company Patent the Basic Components of Psychedelic Therapy?

How to Set an Intention for Your Drug Trip?

by EmpathiCSubstanceS | Nov 8, 2021 | Anxiety, Bipolar Disorder, Cannabis Marijuana, Chronic Pain, Depression, Iboga, Kambo, MDMA Sassafras Molly, Microdosing

A recent mushrooms-and-MDMA trip wasn’t elucidating in the way I’d hoped it might be. I chose to record myself doing psychedelics with a guide, hoping that when I listened back, I’d hear myself having major breakthroughs. What this actually sounded like, when I...
« Older Entries
Next Entries »

IMPORTANT NOTICE:

This community is being designed as a secure space. It is not a place to seek, encourage, or participate in the procurement of controlled substances. Do not bring, buy, sell, transfer, or arrive on any illegal substances, or swap information on how to buy them. Attendees and/or members of this community who violate these basic house rules will be removed from the community and will not be allowed to attend future events.

Psychedelic Research

LSD enhances suggestibility in healthy volunteers

Aug 16, 2022

Volunteers gave significantly higher ratings for the CIS (p = 0.018), but not the MIT (p = 0.11), after LSD than placebo. The magnitude of suggestibility enhancement under LSD was positively correlated with trait conscientiousness measured at baseline (p = 0.0005)....

Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor

Aug 16, 2022

LSD reduced associative, but concurrently increased sensory-somatomotor brain-wide and thalamic connectivity. Ketanserin fully blocked the subjective and neural LSD effects. Whole-brain spatial patterns of LSD effects matched 5-HT2A receptor cortical gene expression...

N,N-dimethyltryptamine and the pineal gland: Separating fact from myth.

Aug 16, 2022

It is clear that very minute concentrations of N,Ndimethyltryptamine have been detected in the brain, but they are not sufficient to produce psychoactive effects. Alternative explanations are presented to explain how stress and near death can produce altered states of...

Psychedelic Medicine

Remembering Dr. Jordi Riba, Ayahuasca Research Pioneer (1968–2020)

Nov 9, 2020

On August 14, 2020, the world bid farewell to scientific pioneer, Dr. Jordi Riba. The untimely death of the Catalan ayahuasca researcher has come as a harsh blow to the close-knit ayahuasca community the world over. Riba was undoubtedly one of the most prolific...

Compass Pathways’ Leads the Way as the First Psychedelics Company To IPO on the Nasdaq FN Media Group Presents Microsmallcap.com Market Commentary

Nov 8, 2020

NEW YORK, Sept. 24, 2020 /PRNewswire/ -- Last year may have been all about cannabis, but it's clear that 2020 and beyond belongs to the psychedelic medicine market. Ever since Johnson & Johnson's (NYSE:JNJ) ketamine-derived medicine, Spravato, received the first...

UC Berkeley launches new center for psychedelic science and education

Nov 8, 2020

Fifty years after political and cultural winds slammed shut the doors on psychedelic research, UC Berkeley is making up for lost time by launching the campus’s first center for psychedelic science and public education. With $1.25 million in seed funding from an...

Colorado’s Nowak Society Launches Public Education Campaign on Psychedelics

Nov 8, 2020

On May 7, 2019, the city of Denver made headlines for becoming the first U.S. city to effectively decriminalize psilocybin mushrooms through its passing of Initiated Ordinance 301 (I-301). In the months that followed, Oakland and Santa Cruz followed suit,...

Company Seeks to Patent Psilocybin for Weight Loss

Nov 8, 2020

Psilocybin has been fast-tracked by the FDA to become a prescription medication in psychedelic-assisted therapy for depression, but now we’re seeing investors line up to support a new indication for the synthetic compound that’s been made famous—in its organic form—by...

© 2025| All Rights Reserved, EntheoMedicine Community
  • Follow
  • Follow
  • Follow
  • Follow